22
Participants
Start Date
January 7, 2015
Primary Completion Date
November 11, 2015
Study Completion Date
August 18, 2016
GPX-150 for Injection
GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
Penn State Milton S Hershey Medical Center, Hershey
University of Iowa Holden Comprehensive Cancer Center, Iowa City
Northwestern University, Chicago
Washington University School of Medicine, St Louis
Lead Sponsor
Gem Pharmaceuticals
INDUSTRY